WO2006044665A3 - Neuroprotective spirostenol pharmaceutical compositions - Google Patents

Neuroprotective spirostenol pharmaceutical compositions Download PDF

Info

Publication number
WO2006044665A3
WO2006044665A3 PCT/US2005/037023 US2005037023W WO2006044665A3 WO 2006044665 A3 WO2006044665 A3 WO 2006044665A3 US 2005037023 W US2005037023 W US 2005037023W WO 2006044665 A3 WO2006044665 A3 WO 2006044665A3
Authority
WO
WIPO (PCT)
Prior art keywords
spirostenol
neuroprotective
pharmaceutical compositions
neurotoxicity
disorder
Prior art date
Application number
PCT/US2005/037023
Other languages
French (fr)
Other versions
WO2006044665A2 (en
Inventor
Zhi-Xing Yao
Laurent Lecanu
Gary Teper
Janet Greeson
Vassilios Papadopoulos
Original Assignee
Univ Georgetown
Samaritan Pharmaceuticals Inc
Zhi-Xing Yao
Laurent Lecanu
Gary Teper
Janet Greeson
Vassilios Papadopoulos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/031,538 external-priority patent/US20060009433A1/en
Application filed by Univ Georgetown, Samaritan Pharmaceuticals Inc, Zhi-Xing Yao, Laurent Lecanu, Gary Teper, Janet Greeson, Vassilios Papadopoulos filed Critical Univ Georgetown
Priority to CA002584333A priority Critical patent/CA2584333A1/en
Priority to JP2007536942A priority patent/JP2008516972A/en
Priority to AU2005295617A priority patent/AU2005295617A1/en
Priority to EP05812949A priority patent/EP1809298A4/en
Publication of WO2006044665A2 publication Critical patent/WO2006044665A2/en
Publication of WO2006044665A3 publication Critical patent/WO2006044665A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a disorder or disease related to, or the symptoms associated with a neurodegenerative disorder such as neurotoxicity or a neuropathology in a subject, particularly to beta-amyloid-induced neurotoxicity and Alzheimer's disease. The invention further provides a method for inducing stem cell differentiation into neuronal cells, by administering to the patient a therapeutically effective amount of a compound of the invention.
PCT/US2005/037023 2004-10-14 2005-10-14 Neuroprotective spirostenol pharmaceutical compositions WO2006044665A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002584333A CA2584333A1 (en) 2004-10-14 2005-10-14 Neuroprotective spirostenol pharmaceutical compositions
JP2007536942A JP2008516972A (en) 2004-10-14 2005-10-14 Pharmaceutical composition of spirostenol having neuroprotective action
AU2005295617A AU2005295617A1 (en) 2004-10-14 2005-10-14 Neuroprotective spirostenol pharmaceutical compositions
EP05812949A EP1809298A4 (en) 2004-10-14 2005-10-14 Neuroprotective spirostenol pharmaceutical compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61869604P 2004-10-14 2004-10-14
US60/618,696 2004-10-14
US11/031,538 2005-01-07
US11/031,538 US20060009433A1 (en) 2003-03-14 2005-01-07 Neuroprotective spirostenol pharmaceutical compositions

Publications (2)

Publication Number Publication Date
WO2006044665A2 WO2006044665A2 (en) 2006-04-27
WO2006044665A3 true WO2006044665A3 (en) 2007-07-05

Family

ID=36203560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/037023 WO2006044665A2 (en) 2004-10-14 2005-10-14 Neuroprotective spirostenol pharmaceutical compositions

Country Status (5)

Country Link
EP (1) EP1809298A4 (en)
JP (1) JP2008516972A (en)
AU (1) AU2005295617A1 (en)
CA (1) CA2584333A1 (en)
WO (1) WO2006044665A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006231451A1 (en) * 2005-04-01 2006-10-12 Georgetown University Use of spirostenols to treat mitochondrial disorders
GB0619860D0 (en) * 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
WO2015163318A1 (en) * 2014-04-25 2015-10-29 レジリオ株式会社 Therapeutic agent for diseases associated with nerve axon dysfunction, including therapeutic agent for alzheimer's disease
WO2024024395A1 (en) * 2022-07-29 2024-02-01 国立大学法人富山大学 Pharmaceutical or food and beverage composition for prevention or treatment of optic nerve disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4303214A1 (en) * 1993-02-04 1994-08-11 Wolfgang Marks Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones
WO1999048507A2 (en) * 1998-03-26 1999-09-30 Phytopharm Plc Steroidal saponins for treating alzheimer's disease
WO2002011708A2 (en) * 2000-08-04 2002-02-14 Symphar S.A. Methods for inducing apolipoprotein e secretion
US6593301B1 (en) * 1997-09-26 2003-07-15 Institute Of Radiation Medicine Use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1496913A4 (en) * 2002-03-15 2007-10-31 Samaritan Pharmaceuticals Inc Neuroprotective spirostenol pharmaceutical compositions
AU2003231427A1 (en) * 2002-04-15 2003-10-27 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Compounds and preparation methods of carboxylate and monoester succinate derivative of diosgenin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4303214A1 (en) * 1993-02-04 1994-08-11 Wolfgang Marks Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones
US6593301B1 (en) * 1997-09-26 2003-07-15 Institute Of Radiation Medicine Use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds
WO1999048507A2 (en) * 1998-03-26 1999-09-30 Phytopharm Plc Steroidal saponins for treating alzheimer's disease
WO2002011708A2 (en) * 2000-08-04 2002-02-14 Symphar S.A. Methods for inducing apolipoprotein e secretion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1809298A4 *
YAO ET AL.: "22R-Hydroxycholesterol Protects Neuronal Cells from Beta-Amyloid-Induced Cytotoxicity by Binding to Beta-Amyloid Peptide", JOURNAL OF NEUROCHEMISTRY, vol. 83, 2002, pages 1110 - 1119, XP003015166 *

Also Published As

Publication number Publication date
EP1809298A4 (en) 2008-06-18
WO2006044665A2 (en) 2006-04-27
AU2005295617A1 (en) 2006-04-27
EP1809298A2 (en) 2007-07-25
JP2008516972A (en) 2008-05-22
CA2584333A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2006124012A3 (en) Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production
EP2331095A4 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014002459A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
UA94909C2 (en) Pharmaceutical composition of a neuroactive steroid and use thereof
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2002043652A3 (en) Anti-proliferative drugs
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
BRPI0712322A2 (en) compounds and combinations thereof for inhibiting beta-amyloid production and methods of using them
NZ596244A (en) Treatment of neurodegenerative diseases
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2008122441A3 (en) Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
WO2005121778A3 (en) Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
WO2010042489A3 (en) Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2006083797A3 (en) Improving and protecting cell therapy for neurological disorders including parkinson's disease
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
WO2007098047A3 (en) Methods and compositions for the treatment of parkinson's disease
WO2006044665A3 (en) Neuroprotective spirostenol pharmaceutical compositions
WO2005072704A3 (en) Method of treating acute rhinosinusitis
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
WO2006101909A3 (en) Combination therapy for treating or preventing diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007536942

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2584333

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005295617

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005812949

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005295617

Country of ref document: AU

Date of ref document: 20051014

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200580042630.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005812949

Country of ref document: EP